Pages that link to "Q44000915"
Jump to navigation
Jump to search
The following pages link to Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. (Q44000915):
Displaying 50 items.
- CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics (Q21090521) (← links)
- Mechanisms of viral entry: sneaking in the front door (Q22252690) (← links)
- HIV-1 entry inhibitors: an overview (Q24645525) (← links)
- Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults (Q24645675) (← links)
- Role of Marine Natural Products in the Genesis of Antiviral Agents (Q26796360) (← links)
- HIV-1 entry inhibitors: recent development and clinical use (Q27003887) (← links)
- In vivo binding and retention of CD4-specific DARPin 57.2 in macaques (Q27320871) (← links)
- Tetraspanins in viral infections: a fundamental role in viral biology? (Q27470936) (← links)
- Crystal Structure of HIV-1 Primary Receptor CD4 in Complex with a Potent Antiviral Antibody (Q27666197) (← links)
- HIV entry inhibitors: mechanisms of action and resistance pathways (Q28296162) (← links)
- Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor (Q33223969) (← links)
- Loss of Asparagine-Linked Glycosylation Sites in Variable Region 5 of Human Immunodeficiency Virus Type 1 Envelope Is Associated with Resistance to CD4 Antibody Ibalizumab (Q33810849) (← links)
- Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36. (Q34174815) (← links)
- Progress in targeting HIV-1 entry. (Q34453555) (← links)
- CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection (Q34473072) (← links)
- Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases (Q34536782) (← links)
- In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor (Q34536817) (← links)
- HIV entry inhibitors and their potential in HIV therapy (Q34595921) (← links)
- Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). (Q34648499) (← links)
- Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20). (Q34680667) (← links)
- The critical need for alternative antiretroviral formulations, and obstacles to their development (Q35164438) (← links)
- Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas (Q35677620) (← links)
- Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry (Q35784750) (← links)
- HIV-1 antiretroviral drug therapy (Q35853012) (← links)
- The brightening future of HIV therapeutics (Q35873262) (← links)
- Monoclonal antibody-based candidate therapeutics against HIV type 1. (Q35904501) (← links)
- A pathophysiological approach to antiretroviral therapy (Q35917460) (← links)
- Clinical experience with therapeutic AIDS vaccines (Q36198648) (← links)
- New antiretroviral agents for the treatment of HIV infection (Q36223750) (← links)
- Emerging drug targets for antiretroviral therapy (Q36237524) (← links)
- HIV entry inhibitors: a new generation of antiretroviral drugs. (Q36262437) (← links)
- Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention (Q36415424) (← links)
- Antibody-based inhibitors of HIV infection (Q36446952) (← links)
- Microbicides and other topical strategies to prevent vaginal transmission of HIV. (Q36460440) (← links)
- Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets (Q36631937) (← links)
- Novel antiretroviral agents in HIV therapy (Q36634459) (← links)
- Novel inhibitors of the early steps of the HIV-1 life cycle (Q36677383) (← links)
- New antiretroviral agents (Q36790196) (← links)
- The growth and potential of human antiviral monoclonal antibody therapeutics. (Q37027166) (← links)
- Next-generation oral preexposure prophylaxis: beyond tenofovir (Q37067126) (← links)
- Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection (Q37088591) (← links)
- Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment. (Q37102101) (← links)
- Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1 (Q37103977) (← links)
- Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity (Q37302902) (← links)
- Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors (Q37388409) (← links)
- Novel compounds for the treatment of HIV type-1 infection (Q37502492) (← links)
- Maraviroc: a new CCR5 antagonist (Q37557671) (← links)
- Lessons learned from HIV vaccine clinical efficacy trials (Q37724091) (← links)
- Recent advances in antiretroviral drugs (Q37779092) (← links)
- Immunotherapeutic restoration in HIV-infected individuals (Q37842335) (← links)